Exelixis
EXEL
#1669
Rank
โ‚น1.246 T
Marketcap
โ‚น4,960
Share price
-1.02%
Change (1 day)
37.98%
Change (1 year)
Exelixis, Inc. is an American genomics-based drug discovery company and the producer of Cometriq, a treatment for medullary thyroid cancer.

EPS for Exelixis (EXEL)

EPS in 2026 (TTM): โ‚น280.56

According to Exelixis's latest financial reports the company's current EPS (TTM) is โ‚น295.94. In 2025 the company made an earnings per share (EPS) of โ‚น273.25.

EPS history for Exelixis from 2013 to 2026

Annual EPS

Year EPS Change
2026 (TTM)โ‚น280.562.68%
2025โ‚น273.25
2023โ‚น61.7714.61%
2022โ‚น53.89-22.97%
2021โ‚น69.97100%
2020โ‚น34.98-65.09%
2019โ‚น100.22-53.91%
2018โ‚น217.47333.96%
2017โ‚น50.11-260.61%
2016-โ‚น31.20-58.75%
2015-โ‚น75.64-42.45%
2014-โ‚น131.425.3%
2013-โ‚น124.81

EPS for similar companies or competitors

Company EPS EPS differencediff. Country
Johnson & Johnson
JNJ
โ‚น826.02 179.12%๐Ÿ‡บ๐Ÿ‡ธ USA
Pfizer
PFE
โ‚น123.86-58.15%๐Ÿ‡บ๐Ÿ‡ธ USA
Amgen
AMGN
โ‚น1,369 362.62%๐Ÿ‡บ๐Ÿ‡ธ USA
Sanofi
SNY
โ‚น242.02-18.22%๐Ÿ‡ซ๐Ÿ‡ท France
Merck
MRK
โ‚น336.35 13.65%๐Ÿ‡บ๐Ÿ‡ธ USA
Bristol-Myers Squibb
BMY
โ‚น336.60 13.74%๐Ÿ‡บ๐Ÿ‡ธ USA
GSK plc
GSK
โ‚น367.45 24.16%๐Ÿ‡ฌ๐Ÿ‡ง UK
Curis
CRIS
-โ‚น347.00-217.25%๐Ÿ‡บ๐Ÿ‡ธ USA
AVEO Oncology
AVEO
-โ‚น79.42-126.84%๐Ÿ‡บ๐Ÿ‡ธ USA